• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性中耳炎的治疗成本效益:观察等待法与阿莫西林治疗的对比

Treatment cost effectiveness in acute otitis media: A watch-and-wait approach versus amoxicillin.

作者信息

Gaboury Isabelle, Coyle Kathryn, Coyle Douglas, Le Saux Nicole

机构信息

Children's Hospital of Eastern Ontario Research Institute;

出版信息

Paediatr Child Health. 2010 Sep;15(7):e14-8. doi: 10.1093/pch/15.7.e14.

DOI:10.1093/pch/15.7.e14
PMID:21886439
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2948781/
Abstract

In Canada, antimicrobial treatment is the most common approach for acute otitis media. The aim of the present study was to compare the cost effectiveness of treatment with amoxicillin versus a watch-and-wait approach (WAIT) within a Canadian pediatric setting. Four hundred eighty-eight children, six months to five years of age, who participated in a randomized controlled trial were included in the study. The average medication costs per patient were higher for the amoxicillin group ($17.26) than for the WAIT group ($4.33). However, both health care ($148.44 versus $162.48) and patient costs ($23.50 versus $31.87) were greater for the WAIT group. The mean cost of treatment for the amoxicillin group was $189.20, compared with $198.68 for the WAIT group. Amoxicillin may be cost effective in treating children with acute otitis media. The potential development of antimicrobial resistance was not addressed in the present study.

摘要

在加拿大,抗菌治疗是急性中耳炎最常见的治疗方法。本研究的目的是比较在加拿大儿科环境中,阿莫西林治疗与观察等待方法(WAIT)的成本效益。参与一项随机对照试验的488名6个月至5岁的儿童被纳入该研究。阿莫西林组每位患者的平均药物成本(17.26美元)高于观察等待组(4.33美元)。然而,观察等待组的医疗保健成本(148.44美元对162.48美元)和患者成本(23.50美元对31.87美元)都更高。阿莫西林组的平均治疗成本为189.20美元,而观察等待组为198.68美元。阿莫西林在治疗急性中耳炎儿童方面可能具有成本效益。本研究未涉及抗菌药物耐药性的潜在发展。

相似文献

1
Treatment cost effectiveness in acute otitis media: A watch-and-wait approach versus amoxicillin.急性中耳炎的治疗成本效益:观察等待法与阿莫西林治疗的对比
Paediatr Child Health. 2010 Sep;15(7):e14-8. doi: 10.1093/pch/15.7.e14.
2
A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age.一项针对6个月至5岁临床诊断为急性中耳炎儿童的阿莫西林随机、双盲、安慰剂对照非劣效性试验。
CMAJ. 2005 Feb 1;172(3):335-41. doi: 10.1503/cmaj.1040771.
3
Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.加替沙星与阿莫西林/克拉维酸治疗儿童复发性中耳炎和急性中耳炎治疗失败的随机、研究者设盲、多中心对比研究。
Pediatr Infect Dis J. 2005 Apr;24(4):301-8. doi: 10.1097/01.inf.0000157084.35865.ba.
4
Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group.依托红霉素与阿莫西林治疗儿童急性中耳炎的多中心、随机、双盲对照研究。急性中耳炎研究组
Eur J Clin Microbiol Infect Dis. 1998 Jul;17(7):470-8. doi: 10.1007/BF01691129.
5
Amoxicillin/clavulanic acid is ineffective at preventing otitis media in children with presumed viral upper respiratory infection: a randomized, double-blind equivalence, placebo-controlled trial.阿莫西林/克拉维酸对预防疑似病毒性上呼吸道感染儿童的中耳炎无效:一项随机、双盲等效性、安慰剂对照试验。
Br J Clin Pharmacol. 2002 Dec;54(6):652-6. doi: 10.1046/j.1365-2125.2002.t01-6-01689.x.
6
A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children.儿童急性中耳炎5种治疗策略的成本效用分析
J Pediatr. 2017 Oct;189:54-60.e3. doi: 10.1016/j.jpeds.2017.05.047. Epub 2017 Jun 28.
7
A placebo-controlled trial of antimicrobial treatment for acute otitis media.一项抗生素治疗急性中耳炎的安慰剂对照试验。
N Engl J Med. 2011 Jan 13;364(2):116-26. doi: 10.1056/NEJMoa1007174.
8
Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population.儿科医疗补助人群中与中耳炎相关的抗生素处方模式、治疗结果及费用支出
Pediatrics. 1997 Oct;100(4):585-92. doi: 10.1542/peds.100.4.585.
9
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.急性中耳炎:肺炎球菌耐药时代的管理与监测——耐多药肺炎链球菌治疗工作组报告
Pediatr Infect Dis J. 1999 Jan;18(1):1-9.
10
[Prevention of acute otitis media. Amoxicillin versus glycoproteins from Klebsiella pneumoniae. Study in children under 5 years of age].[急性中耳炎的预防。阿莫西林与肺炎克雷伯菌糖蛋白的对比。针对5岁以下儿童的研究]
Presse Med. 1992 Mar 21;21(11):509-14.

引用本文的文献

1
Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population: A cost-utility analysis.13价、15价和20价肺炎球菌结合疫苗在加拿大儿科人群中的比较:一项成本效用分析。
Can Commun Dis Rep. 2025 Feb 12;51(2-3):68-83. doi: 10.14745/ccdr.v51i23a02. eCollection 2025 Feb.
2
A trial-based cost-effectiveness analysis of antibiotic prescription strategies for non-complicated respiratory tract infections in children.基于试验的儿童非复杂性呼吸道感染抗生素处方策略的成本效果分析。
BMC Pediatr. 2023 Oct 2;23(1):497. doi: 10.1186/s12887-023-04235-3.
3
Implantable Devices for Single-Sided Deafness and Conductive or Mixed Hearing Loss: A Health Technology Assessment.用于单侧耳聋及传导性或混合性听力损失的植入式设备:一项卫生技术评估
Ont Health Technol Assess Ser. 2020 Mar 6;20(1):1-165. eCollection 2020.
4
Bilateral Cochlear Implantation: A Health Technology Assessment.双侧人工耳蜗植入:一项卫生技术评估。
Ont Health Technol Assess Ser. 2018 Oct 24;18(6):1-139. eCollection 2018.
5
Incidence and economic burden of acute otitis media in children aged up to 5years in three Middle Eastern countries and Pakistan: A multinational, retrospective, observational study.中东三个国家和巴基斯坦5岁以下儿童急性中耳炎的发病率和经济负担:一项跨国、回顾性、观察性研究。
J Epidemiol Glob Health. 2017 Jun;7(2):123-130. doi: 10.1016/j.jegh.2016.12.004. Epub 2017 Feb 8.

本文引用的文献

1
Management of acute otitis media.急性中耳炎的管理
Paediatr Child Health. 2009 Sep;14(7):457-64.
2
Comparison of two approaches to observation therapy for acute otitis media in the emergency department.急诊科急性中耳炎两种观察治疗方法的比较
Pediatrics. 2008 May;121(5):e1352-6. doi: 10.1542/peds.2007-2278.
3
Acute mastoiditis: increase in the incidence and complications.急性乳突炎:发病率及并发症增加。
Int J Pediatr Otorhinolaryngol. 2007 Jul;71(7):1007-11. doi: 10.1016/j.ijporl.2007.02.014. Epub 2007 May 9.
4
Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial.观察等待疗法治疗急性中耳炎:一项随机对照试验
JAMA. 2006 Sep 13;296(10):1235-41. doi: 10.1001/jama.296.10.1235.
5
Community prescribing and resistant Streptococcus pneumoniae.社区处方与耐肺炎链球菌
Emerg Infect Dis. 2005 Jun;11(6):829-37. doi: 10.3201/eid1106.050198.
6
A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age.一项针对6个月至5岁临床诊断为急性中耳炎儿童的阿莫西林随机、双盲、安慰剂对照非劣效性试验。
CMAJ. 2005 Feb 1;172(3):335-41. doi: 10.1503/cmaj.1040771.
7
Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.在细菌耐药时代优化儿童社区获得性呼吸道感染的抗菌治疗
Clin Pediatr (Phila). 2004 Mar;43(2):135-51. doi: 10.1177/000992280404300203.
8
Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample.七价肺炎球菌结合疫苗时代的耐抗生素肺炎链球菌:多社区样本中携带情况的预测因素
Pediatrics. 2003 Oct;112(4):862-9. doi: 10.1542/peds.112.4.862.
9
A cross-national study of acute otitis media: risk factors, severity, and treatment at initial visit. Report from the International Primary Care Network (IPCN) and the Ambulatory Sentinel Practice Network (ASPN).一项关于急性中耳炎的跨国研究:初诊时的危险因素、严重程度及治疗。国际初级保健网络(IPCN)和门诊哨点实践网络(ASPN)的报告。
J Am Board Fam Pract. 2001 Nov-Dec;14(6):406-17.
10
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.生活在偏远农村社区的健康儿童中肺炎链球菌多重抗生素耐药率高:与头孢菌素使用及家庭内传播的关联
Pediatrics. 2001 Oct;108(4):856-65. doi: 10.1542/peds.108.4.856.